Cytokine profiles of mild-to-moderate SARS-CoV-2 infected and recovered pre-vaccinated individuals residing in Indonesia.

Publisher: PeerJ Inc Country of Publication: United States NLM ID: 101603425 Publication Model: eCollection Cited Medium: Internet ISSN: 2167-8359 (Electronic) Linking ISSN: 21678359 NLM ISO Abbreviation: PeerJ Subsets: MEDLINE

Original Publication: Corte Madera, CA : PeerJ Inc.

COVID-19*/blood ; COVID-19*/immunology ; COVID-19*/epidemiology ; COVID-19*/prevention & control ; Cytokines*/blood ; SARS-CoV-2*/immunology; Humans ; Indonesia/epidemiology ; Male ; Female ; Adult ; Middle Aged ; Severity of Illness Index ; Case-Control Studies ; Young Adult ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/administration & dosage

Background: Accumulating evidence suggests the involvement of cytokine-mediated inflammation, in clinical severity and death related to SARS-CoV-2 infection, especially among pre-vaccinated individuals. An increased risk of death was also described among SARS-CoV-2 recovered individuals, which might be correlated with prolonged inflammatory responses. Despite being among the countries with the highest cumulative deaths due to COVID-19, evidence regarding cytokine profiles among SARS-CoV-2 infected and recovered pre-vaccinated individuals in Indonesia is scarce. Thus, this study aimed to describe the cytokines profiles of pre-vaccinated individuals residing in Indonesia, with mild-to-moderate SARS-CoV-2 infection and those who recovered.
Methods: Sixty-one sera from 24 hospitalized patients with mild-to-moderate SARS-CoV-2 infection, 24 individuals recovered from asymptomatic-to-moderate SARS-CoV-2 infection, and 13 healthy controls unexposed to SARS-CoV-2 were used in this study. Quantification of serum cytokine levels, including IL-6, IL-8, IP-10, TNF- α , CCL-2, CCL-3, CCL-4, and CXCL-13, was performed using a Luminex multi-analyte-profiling (xMAP)-based assay.
Results: The levels of IL-8 along with CCL-2 and CCL-4, were significantly higher ( p  ≤ 0.01) in hospitalized patients with mild-to-moderate SARS-CoV-2 infection and recovered individuals compared to healthy controls. However, no significant difference was observed in these cytokine levels between infected and recovered individuals. On the other hand, there were no significant differences in several other cytokine levels, including IL-6, IL-10, TNF- α , CCL-3, and CXCL-13, among all groups.
Conclusion: IL-8, CCL-2, and CCL-4 were significantly elevated in pre-vaccinated Indonesian individuals with mild-to-moderate SARS-CoV-2 infection and those who recovered. The cytokine profiles described in this study might indicate inflammatory responses not only among SARS-CoV-2 infected, but also recovered individuals.
Competing Interests: The authors declare there are no competing interests.
(©2024 Megasari et al.)

PeerJ. 2023 Sep 25;11:e16142. (PMID: 37780375)
Biol Sex Differ. 2021 Dec 20;12(1):66. (PMID: 34930441)
Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):249-54. (PMID: 26283530)
Front Immunol. 2020 Jul 10;11:1708. (PMID: 32754163)
Signal Transduct Target Ther. 2020 Jun 19;5(1):100. (PMID: 32561706)
Viruses. 2022 Feb 23;14(3):. (PMID: 35336861)
Acta Biomed. 2020 Mar 19;91(1):157-160. (PMID: 32191675)
Lancet Reg Health Eur. 2022 Jul;18:100394. (PMID: 35505834)
Medicine (Baltimore). 2021 Jun 18;100(24):e26371. (PMID: 34128896)
Front Genet. 2021 Jun 07;12:680646. (PMID: 34163532)
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1770-1776. (PMID: 35302230)
PLoS One. 2022 Jan 25;17(1):e0262438. (PMID: 35077495)
Virol J. 2022 May 26;19(1):92. (PMID: 35619180)
Front Pharmacol. 2022 Feb 14;13:802228. (PMID: 35237162)
J Am Med Dir Assoc. 2022 Mar;23(3):434-439. (PMID: 35219507)
Int J Biol Sci. 2022 Jan 1;18(2):459-472. (PMID: 35002503)
Nat Med. 2020 Jun;26(6):842-844. (PMID: 32398875)
J Gerontol A Biol Sci Med Sci. 2010 Apr;65(4):429-33. (PMID: 20018825)
Lancet Reg Health Southeast Asia. 2023 Mar;10:100130. (PMID: 36531927)
J Am Med Dir Assoc. 2013 Dec;14(12):877-82. (PMID: 23792036)
Forensic Sci Med Pathol. 2022 Mar;18(1):4-19. (PMID: 34463916)
Int Immunopharmacol. 2022 Dec;113(Pt A):109325. (PMID: 36252475)
Emerg Microbes Infect. 2020 Dec;9(1):761-770. (PMID: 32228226)
mSphere. 2021 Jan 20;6(1):. (PMID: 33472985)
Front Immunol. 2021 Jan 29;12:626235. (PMID: 33584733)
Nat Immunol. 2023 Apr;24(4):604-611. (PMID: 36879067)
Nature. 2023 Nov;623(7985):139-148. (PMID: 37748514)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Nat Rev Microbiol. 2019 Mar;17(3):181-192. (PMID: 30531947)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Nature. 2020 Dec;588(7837):315-320. (PMID: 32846427)
Signal Transduct Target Ther. 2020 Dec 14;5(1):292. (PMID: 33318472)
Viruses. 2022 Nov 28;14(12):. (PMID: 36560669)
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2. (PMID: 32407669)
PLoS One. 2021 May 6;16(5):e0251234. (PMID: 33956869)
Nat Immunol. 2022 Feb;23(2):210-216. (PMID: 35027728)
Int J Mol Sci. 2022 Aug 13;23(16):. (PMID: 36012323)
Nat Biotechnol. 2020 Aug;38(8):970-979. (PMID: 32591762)
Cytokine Growth Factor Rev. 2021 Apr;58:82-91. (PMID: 33573850)
Front Public Health. 2022 Aug 26;10:873596. (PMID: 36091533)
Front Immunol. 2021 Nov 09;12:771609. (PMID: 34858428)
Front Cell Infect Microbiol. 2022 Jun 30;12:922422. (PMID: 35846757)
Lancet. 2020 Mar 28;395(10229):1033-1034. (PMID: 32192578)
Rev Med Virol. 2020 Nov;30(6):1-9. (PMID: 32845568)
Lancet Infect Dis. 2022 Dec;22(12):1651-1652. (PMID: 36030797)
Int J Clin Pract. 2021 Dec;75(12):e14970. (PMID: 34626520)
Eur Cytokine Netw. 2020 Jun 1;31(2):44-49. (PMID: 32933891)
Aging Cell. 2019 Feb;18(1):e12865. (PMID: 30430748)
Eur J Clin Invest. 2021 Jan;51(1):e13429. (PMID: 33058143)
Front Immunol. 2021 Jan 08;11:602395. (PMID: 33488599)
Int J Inflam. 2011;2011:908468. (PMID: 22235381)
JCI Insight. 2020 Jul 9;5(13):. (PMID: 32501293)

Keywords: COVID-19; Inflammatory cytokines; Mild-to-moderate infection; SARS-CoV-2; Vaccination

0 (Cytokines)
0 (COVID-19 Vaccines)

Date Created: 20240422 Date Completed: 20240423 Latest Revision: 20240426

20240426

PMC11032655

10.7717/peerj.17257

38646483